The sector came close to getting above recent highs but seemed to touch them and then pullback. It was not necessarily a bad day for the sector but also did not quite break the potential downtrend. There seems to be some positive news last night and this morning, so perhaps that will be enough to […]
We are really close to breaking above the recent high and that would be very positive as it stops a lower high from being formed. It has not happened yet and we could still fail but if the momentum continues it would be even more positive as it would have been done without M&A being […]
Well, that was quite the bounce yesterday. The morning start off well especially given the lack of market moving news but then a grind higher turned into a run. I would look at the highs of July 27th and July 28th as key levels. Despite the great move, if we cannot break above those levels […]
It looked grim Friday for the sector. It simply could not catch a bid. I am sure most (all) of use tried not to think about the price action this weekend and were resigned to more selling. Today, however, we get a bounce. What is interesting is that having being a couple days removed from […]
Founded in 2011, Chimera Research Group provides completely independent and actionable investment and trading ideas backed by comprehensive fundamental research and analysis for listed companies in the biotech and pharmaceutical sectors. Our coverage focuses on early stage companies with impending FDA decisions or clinical trial results but also includes mid-to-large cap bio-pharma companies where there exists specific catalysts. Our Trade Ideas are designed to maximize the risk reward profile. Our Research Reports outline the top up-and-coming catalysts that represent the best opportunities for traders and investors.
The biopharmaceutical sector offers significant opportunities to generate big returns yet can be risky and difficult to navigate.
Subscribe to Chimera Research Group and proceed with confidence.